Snapshot from Sep 04, 2026 at 07:00 UTC. For live data and tracking: View Live
Accidents Ebola outbreak

DR Congo Ebola outbreak deaths top 3,000

Analysis based on 128 articles · First reported Aug 13, 2026 · Last updated Sep 02, 2026

Sentiment
-70
Attention
6
Articles
128
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The outbreak heightens demand for Ebola vaccines and treatments, benefiting developers like Merck and Moderna, though uncertainty over cross-protection and trial outcomes tempers sentiment. It also strains humanitarian budgets and could disrupt regional trade and travel, particularly in Central Africa, but global market impact remains limited.

Healthcare Pharmaceuticals Humanitarian Aid

The Democratic Republic of the Congo is experiencing its deadliest Ebola outbreak on record, caused by the rare Bundibugyo strain. As of early September 2026, government data show over 6,100 confirmed cases and more than 3,000 deaths, with a fatality rate near 49%. The outbreak, declared in mid-May, has spread to six provinces, fueled by conflict, displacement, attacks on health workers, and weak health infrastructure. The World Health Organization warns it is on track to surpass the 2014-2016 West Africa outbreak, the deadliest ever. No vaccine or treatment is approved for Bundibugyo, but authorities have begun vaccinating frontline workers with Merck's Ervebo vaccine, which is licensed for the Zaire strain and may offer cross-protection. Clinical trials are underway for Bundibugyo-specific vaccines, including candidates from Moderna and the University of Oxford. The UN and partners have called for increased funding, with the response plan seeking over $1 billion, while insecurity and community mistrust hamper containment efforts. Neighboring countries, especially Burundi and the Central African Republic, are on alert for potential spillover.

91 World Health Organization assessed risk
90 Merck Group provided Ervebo vaccine Democratic Republic of the Congo
84 Moderna developed vaccine candidate
80 Merck Group developed vaccine
79 World Health Organization declared emergency
79 United States invoked public health law
78 Hilleman Laboratories announced development
78 International AIDS Vaccine Initiative developing Bundibugyo-specific vaccine
75 World Health Organization recommended prioritizing antibodies
75 Democratic Republic of the Congo received vaccine doses
+ 36 more actions View on Dashboard
cnt
Epicenter of the outbreak; faces severe public health crisis, economic disruption, and strained health system.
Importance 100.0 Sentiment -80.0
ngo
Coordinates international response, deploys experts, and recommends vaccine trials; faces criticism over funding gaps.
Importance 90.0 Sentiment 20.0
govactor
Provides official case and death data; leads vaccination campaign and response efforts.
Importance 90.0 Sentiment -50.0
loc
Democratic Republic of the Congo — Ituri Province is the epicenter of the outbreak, with the highest number of cases and deaths. The region's insecurity and weak infrastructure complicate the response and exacerbate the crisis.
Importance 80.0 Sentiment -60.0
alliance
Mobilizes agencies and calls for $1.1 billion in additional funding; Secretary-General urges global action.
Importance 80.0 Sentiment 10.0
per
WHO Director-General urges scaled-up response and warns of unknown transmission chains.
Importance 70.0 Sentiment 20.0
govactor
Supports regional response, coordinates with WHO, and estimates outbreak may be three times larger than reported.
Importance 70.0 Sentiment 20.0
stock
Manufacturer of Ervebo vaccine; deployed under compassionate use and clinical trials, potential revenue boost.
Importance 70.0 Sentiment 40.0
per
UN Secretary-General publicly appeals for funding and condemns 'indifference' to the outbreak.
Importance 60.0 Sentiment 10.0
ngo
Operates treatment centers and provides medical aid in affected areas; faces security challenges.
Importance 60.0 Sentiment 30.0
govactor
Partner in the studies, providing cohorts and laboratory expertise, and will receive transferred laboratory methods from ITM.
Importance 55.0 Sentiment 50.0
ngo
Received $1.02 million for the EBO-BOOST-BRIDGE project to analyze samples from over 600 participants for cross-protection against Bundibugyo.
Importance 55.0 Sentiment 50.0
ngo
UNICEF is mobilizing influencers and artists, including Lokua Kanza, to raise awareness and promote preventive measures among young people.
Importance 50.0 Sentiment -10.0
ngo
Reports attacks on volunteers and ambulances; calls for protection of humanitarian workers.
Importance 50.0 Sentiment 10.0
ngo
Funds $4.17 million in research to assess cross-protection of existing vaccines against Bundibugyo.
Importance 50.0 Sentiment 30.0
+ 37 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.